Form 4: Sath Shukla, CEO of Spero Therapeutics, Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Sath Shukla, CEO of Spero Therapeutics, sold 2,757 shares of common stock on August 27, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On August 27, 2024, Sath Shukla, the CEO and President of Spero Therapeutics, sold 2,757 shares of common stock.
- The sale was executed at a price of $1.35 per share.
- This transaction was done to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted to Shukla on August 26, 2021.
- Following the transaction, Shukla still beneficially owns 1,140,809 shares of Spero Therapeutics.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among corporate executives. This transaction reflects a standard part of executive compensation and equity management.
Key Dates
| Date | Description |
|---|---|
| 08/26/2021 | Date RSUs were granted to Sath Shukla. |
| 08/27/2024 | Date of the stock sale transaction. |
| 08/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.